Parexel, a global clinical development partner to the world’s life sciences industry, has acquired Vitrana, a provider of an AI-enabled, end-to-end pharmacovigilance (PV) technology platform.
The acquisition provides an integrated PV platform that leverages intelligent automation and AI to accelerate end-to-end Patient Safety & PV processes, deliver first-time quality and enhance compliance. The technology platform is system-agnostic and integrates with any safety database – allowing customers to deploy the capabilities that best fit their needs – improving accuracy, cycle times and delivering measurable and sustainable efficiencies. The acquisition underscores Parexel’s continued investment in AI-enabled solutions across clinical development from regulatory submissions to trial execution and now patient safety.
“With Vitrana, we can now offer customers a single partner for both PV technology and services – and that changes what we can deliver for them. Our customers will benefit from best-in-class, technology-enabled PV services that handle growing regulatory volume and complexity, enhance compliance, streamline workflows, and enable experts to focus on what matters most: product and patient safety,” said Sanjay Vyas, President of Patient Safety Services & Clinical Logistics and Managing Director of India, Parexel. “This acquisition aligns with Parexel’s commitment to operational excellence and enables us to deliver year-over-year operational and efficiency gains to customers while maintaining the highest standards of quality delivery across patient safety operations.”
“We’re thrilled to join Parexel and further scale our proven technology and our experienced team as we strengthen pharmacovigilance solutions,” said Mohit Gupta, President and CEO, Vitrana. “Together, we can offer improved efficiency, quality and compliance for our customers worldwide.”
Vitrana’s team and technology will be aligned with Parexel’s Patient Safety Services organization, providing a seamless transition and continuity of services to customers. During this transition period, the business will be “Vitrana – a Parexel Company,” with phased integration aligned to customer commitments and product roadmap milestones.
Other Pharma Industry Acquisitions
Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.
